Skip to main content

Advertisement

Table 1 RCT’s of NOACs vs . Warfarin in acute therapy of VTE

From: Venous thromboembolism in the elderly: efficacy and safety of non-VKA oral anticoagulants

Author, year Trial name Drug and dose Initial regimen N pts, overall N pts ≥75 years (%) N pts CrCl ≤50 ml/min (%)
Schulman, 2009 Schulman, 2014 RE-COVER I-II Dabigatran 150 mg bd Heparin lead-in 5107 259 (12) 167 (5.2)
Bauersachs, 2010 Buller, 2012 EINSTEIN DVT-PE Rivaroxaban 20 mg od Rivaroxaban 15 mg bd for 3 weeks 8281 1283 (18) 664 (8.0)
Agnelli, 2013 AMPLIFY Apixaban 5 mg bd Apixaban 10 mg bd for 1 week 5395 768 (14) 327 (6.2)
Buller, 2013 HOKUSAI Edoxaban 60 or 30* mg od Heparin lead-in 8292 1004 (12) 541 (6.6)
  1. RCT, randomized controlled trial; bd, bis in die; od, omne in die. RE-COVER I-II [17, 18, 22]; EINSTEIN [1416, 19, 23]; AMPLIFY [1]; HOKUSAI [3] - *30 mg od in patients with CrCl 30-50 ml/min, body weight <60 kg or concommitant use of strong Pgp inhibitors.